Lurasidone

Lurasidone
	Above: molecular structure of lurasidone
Clinical data
Pronunciation	/ljʊəˈræsɪˌdoʊn/
Trade names	Latuda, others
Other names	SM-13496
AHFS/Drugs.com	Monograph
MedlinePlus	a611016
License data	US DailyMed: Lurasidone;
Pregnancy; category	AU: B1;
Routes of; administration	By mouth
Drug class	Atypical antipsychotic
ATC code	N05AE05 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only) ; BR: Class C1 (Other controlled substances) ; CA: ℞-only ; UK: POM (Prescription only) ; US: ℞-only ; EU: Rx-only ; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	9–19% (oral)
Protein binding	~99%
Metabolism	Liver (CYP3A4-mediated)
Elimination half-life	18–40 hours
Excretion	Faecal (67–80%),; renal (9–19%)
Identifiers
	IUPAC name (3aR,4S,7R,7aS)-2-[((1R,2R)-2-{[4-(1,2-benzisothiazol-3-yl)piperazin-1-yl]methyl}cyclohexyl)methyl]-4,7-methano-1,3,3a,4,5,6,7,7a-octahydro-2H-isoindole-1,3-dione;
CAS Number	367514-87-2;
PubChem CID	213046;
IUPHAR/BPS	7461;
DrugBank	DB08815;
ChemSpider	184739;
UNII	22IC88528T;
KEGG	D04820;
ChEBI	CHEBI:70735 ;
ChEMBL	ChEMBL1237021;
CompTox Dashboard (EPA)	DTXSID40870340 ;
ECHA InfoCard	100.225.187
Chemical and physical data
Formula	C28H36N4O2S
Molar mass	492.68 g·mol−1
3D model (JSmol)	Interactive image;
Specific rotation	[α]20D −59°
Melting point	176 to 178 °C (349 to 352 °F)
Solubility in water	0.224
	SMILES O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1;
	InChI InChI=1S/C28H36N4O2S/c33-27-24-18-9-10-19(15-18)25(24)28(34)32(27)17-21-6-2-1-5-20(21)16-30-11-13-31(14-12-30)26-22-7-3-4-8-23(22)35-29-26/h3-4,7-8,18-21,24-25H,1-2,5-6,9-17H2/t18-,19+,20-,21-,24+,25-/m0/s1; Key:PQXKDMSYBGKCJA-CVTJIBDQSA-N;

Lurasidone, sold under the brand name Latuda, is an atypical antipsychotic medication that is used to treat schizophrenia and bipolar depression. It is taken by mouth.

It was first approved for medical use in the United States in 2010. In 2013, it was approved in Canada and by the U.S. Food and Drug Administration (FDA) to treat bipolar depression, either as on its own (monotherapy) or adjunctively with lithium or valproate. It was first approved for medical use in the United States in 2010. In 2013, it was approved in Canada and by the U.S. Food and Drug Administration (FDA) to treat bipolar depression, either as on its own (monotherapy) or adjunctively (together) with lithium or valproate.

This short article about medicine can be made longer. You can help Wikipedia by adding to it.

References

↑ "Lurasidone (Latuda) Use During Pregnancy". Drugs.com. 5 February 2020. Archived from the original on 15 October 2020. Retrieved 12 May 2020.
1 2 3 "Lurasidone Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 21 March 2019. Retrieved 21 March 2019.
1 2 3 4 5 "Product information Latuda (lurasidone hydrochloride)" (PDF). TGA eBusiness Services. Therapeutic Goods Administration. 28 October 2022. Archived from the original on 28 October 2022. Retrieved 28 October 2022.
↑ "Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 10 April 2023. Retrieved 10 April 2023.
↑ Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.
↑ "Latuda 18.5mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 16 January 2019. Archived from the original on 14 October 2020. Retrieved 12 May 2020.
↑ "Latuda- lurasidone hydrochloride tablet, film coated". DailyMed. Archived from the original on 28 August 2021. Retrieved 12 May 2020.
↑ "Latuda EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 11 August 2020. Retrieved 12 May 2020. This article incorporates text from this source, which is in the public domain.
1 2 3 "Latuda: EPAR – Product Information" (PDF). European Medicines Agency. 14 April 2016. Archived (PDF) from the original on 21 August 2016. Retrieved 27 February 2017.

[Drugs.com_pregnancy-1] "Lurasidone (Latuda) Use During Pregnancy". Drugs.com. 5 February 2020. Archived from the original on 15 October 2020. Retrieved 12 May 2020.

[AHFS2019-2] 1 2 3 "Lurasidone Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 21 March 2019. Retrieved 21 March 2019.

[TGA-3] 1 2 3 4 5 "Product information Latuda (lurasidone hydrochloride)" (PDF). TGA eBusiness Services. Therapeutic Goods Administration. 28 October 2022. Archived from the original on 28 October 2022. Retrieved 28 October 2022.

[4] "Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 10 April 2023. Retrieved 10 April 2023.

[5] Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.

[6] "Latuda 18.5mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 16 January 2019. Archived from the original on 14 October 2020. Retrieved 12 May 2020.

[Latuda_label-7] "Latuda- lurasidone hydrochloride tablet, film coated". DailyMed. Archived from the original on 28 August 2021. Retrieved 12 May 2020.

[Latuda_EPAR-8] "Latuda EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 11 August 2020. Retrieved 12 May 2020. This article incorporates text from this source, which is in the public domain.

[EMA-9] 1 2 3 "Latuda: EPAR – Product Information" (PDF). European Medicines Agency. 14 April 2016. Archived (PDF) from the original on 21 August 2016. Retrieved 27 February 2017.